Hot Topics in Sarcoma: Precision and Perspectives

In Naples, today December 5th and tomorrow, the important scientific meeting "Hot Topics on Sarcomas: Precision, Proximity, ...
The American Journal of Managed Care

When to Observe Desmoid Tumors

Experts discuss the complexities of observing desmoid tumors, weighing the benefits of active surveillance against the need ...
TipRanks on MSN

Immunome initiated with a Buy at Truist

Truist analyst Karina Rabayeva initiated coverage of Immunome (IMNM) with a Buy rating and $36 price target The company’s lead asset, ...
The American Journal of Managed Care

The Burden and Unmet Needs Associated with Desmoid Tumors

Patients with desmoid tumors face significant clinical and economic burdens, impacting their quality of life and leading to ...
Investing

Stephens raises Immunome stock price target to $33 on varegacestat potential

The price target increase reflects Stephens’ strengthened conviction in the longer-term potential of Immunome’s varegacestat treatment for desmoid tumors, which is expected to present top-line data ...
BioSpace

Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors

Milestone follows disclosure of compelling preliminary data presented at the ESMO Congress and the CTOS 2025 Annual Meeting showing clinically meaningful anti-tumor activity in desmoid tumors ...
Enid News & Eagle

Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced that the U.S. Food and Drug Administration ...